NCT04191616 2025-09-04
SELECT
Amgen
Phase 2 Completed
Clinical Trials
18 trialsNCT03834506 2025-07-18
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02654990 2024-07-12
PANORAMA_3
pharmaand GmbH
Phase 2 Completed
NCT04907227 2024-07-12
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT01626664 2024-04-25
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT03151811 2024-01-30
OCEAN
Oncopeptides AB
Phase 3 Terminated
NCT03481556 2022-12-19
ANCHOR
Oncopeptides AB
Phase 1/2 Terminated
NCT01335399 2022-09-30
ELOQUENT - 1
Bristol-Myers Squibb
Phase 3 Completed
NCT01239797 2022-06-01
ELOQUENT - 2
Bristol-Myers Squibb
Phase 3 Completed
NCT02036502 2021-04-08
MK-3475-023
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00773838 2021-04-01
MK-0683-095
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00642954 2020-11-18
MK-0683-074
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00928486 2019-11-20
A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma
Celgene
Phase 3 Completed
NCT01636947 2018-09-25
KMEC
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT02720510 2018-07-24
PANORAMA4
Novartis
Phase 2 Terminated
NCT01393964 2017-08-03
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
Bristol-Myers Squibb
Phase 1 Completed
NCT00179647 2010-03-16
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
Celgene
Phase 3 Completed
NCT00474188 2009-09-02
A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Celgene
Phase 2 Terminated